StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
PSTVCERENOME, INC.
stockpulse.co.kr
$3.87▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $26.6MShares out 6.9M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

1
  • 8.4After-hours26.08.05 05:30
    8-KKey event#●●●#●●●

    CERENOME, INC.

    Plus Therapeutics, Inc.는 2026년 8월 3일부로 사명을 Cerenome, Inc.로 변경했습니다. 이에 따라 나스닥 상장 종목 코드(Ticker)도 기존 'PSTV'에서 'CNSY'로 변경되어 거래가 시작되었습니다.…more

    $3.87+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare

News

GlobeNewswire
  • 8.14After-hours26.08.15 05:15
    #●●●#●●●#●●●

    Cerenome Reports Q2 2026 Financial Results and Business Update

    Cerenome announced its second-quarter financial results alongside updates on the clinical progress of its REYOBIQ therapy and the commercial expansion of its CNSide diagnostic platform. The company is focusing on achieving key clinical milestones by year-end while strengthening its diagnostic commercial organization following its recent rebranding.…more

    $3.87+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 8.13Pre-market26.08.13 20:30

    ●●●●●●●● ●●●●● ●●●●●●

    Cerenome has signed an in-network agreement with HCSC, expanding insurance coverage for its CNSide diagnostic test to over 150 million lives. This milestone exceeds the company's 2026 commercial coverage goal ahead of schedule, supporting increased clinical adoption.…more

    $3.87+0.00%vs prev close
    Read sourceShareGlobeNewswire
  • 7.31Pre-market26.07.31 21:30

    ●●●●●●●● ●●●●● ●●●●●●

    플러스 테라퓨틱스가 사명을 '세레놈(Cerenome)'으로 변경하고 티커를 CNSY로 교체하며 중추신경계 종양 통합 플랫폼 기업으로 새롭게 출발합니다. 진단, 치료제, AI 기술을 결합해 사업 영역을 확장하며 장기적인 기업 가치 제고를 목표로 합니다.…more

    $3.87+0.00%vs prev close
    Read sourceShareGlobeNewswire

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →